Change in IgG and evolution of lung function in children with cystic fibrosis  by Proesmans, M. et al.
Journal of Cystic Fibrosis 10 (2011) 128–131
www.elsevier.com/locate/jcfOriginal Article
Change in IgG and evolution of lung function in children with cystic fibrosis
M. Proesmans a,⁎, C. Els b, F. Vermeulen a, K. De Boeck a
a Dept. Pediatrics, Pediatric Pulmonology University Hospital of Leuven, Belgium
b Dept. Pediatrics, Pediatric Pulmonology University of Pretoria, South Africa
Received 5 October 2010; received in revised form 6 December 2010; accepted 9 December 2010Abstract
Reports from the seventies and eighties have shown that cystic fibrosis (CF) patients with severe lung disease have high levels of IgG and that
this is associated with worse prognosis. We decided to explore IgG level as a possible outcome parameter for lung disease severity in a cohort of
pediatric CF patients treated according to current standards of care.
Seventy three CF children older than 5 years (and max 15 years old at the initial evaluation) attending the same CF center were followed during
a period of 4 years. Data collection included spirometry, height, weight, sputum cultures and total IgG.
Median age at the start was 10 years. IgG z scoresb2 SD were seen in 2.7% of patients in 2004 and 2008. Twelve patients (16%) had an
IgGN2 SD in 2004 and this number increased to 18 (25%) in 2008. IgG z-scores were inversely correlated with FEV1% predicted (r=−0.323 in
2004; pb .001). In longitudinal evaluation, changes in IgG z-score correlate inversely with changes in FEV1% predicted (r=−0.498; pb .001).
We can conclude that even for CF patients treated according to current standards IgG z-score increases with age and is correlated with a decline
in FEV1.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Cystic fibrosis (CF) lung disease is characterized by chronic
endobronchial infection and inflammation, typically caused by
bacteria such as S. aureus and P. aeruginosa (Pa) [1]. It has
been reported several decades ago, that CF patients with severe
lung disease have raised levels of immunoglobuline G (IgG) [2].
All IgG subclass levels are also raised in these patients [3,4]. On
the other hand old reports document hypo-gammaglobulinemia
in up to 10.8% of children with CF [2]. Although the latter
finding is still poorly understood, a relation with malnutrition
was suspected.
In the above mentioned reports, high levels of IgG were in a
cross sectional analysis associated with worse lung function as
higher IgG would reflect more severe chronic lung infection [5].
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doi:10.1016/j.jcf.2010.12.004was associated with better lung function and thus prognosis [5].
These older data therefore suggest that IgG level and evolution
could have a potential as an outcome parameter.
Over the past decades CF therapy has progressed with
intensive nutritional support and aggressive treatment of lung
infection as major cornerstones. Frequent and prolonged
courses of oral, inhaled and intravenous antibiotics are being
prescribed to slow down relentless lung infection [6].
Additionally new mucolytics have become available [7]. Few
studies have addressed the prevalence of hyper- and/or hypo-
gammaglobulinemia and its relation with lung prognosis in CF
children treated according to current standards. One pediatric
CF center reported hyper IgG (N2 SD for age) in 7.8% (n=12)
while only 1.9% (n=3) had hypo IgG [8]. The former group had
worse lung function and worse clinical and radiological scores
when compared to matched control CF patients.
Because recent data are limited and cross sectional, we
decided to study the relation between IgG and lung function
over a 4 year period in a cohort of pediatric CF patients thereby
exploring IgG level as a possible outcome parameter for lung
disease severity.d by Elsevier B.V. All rights reserved.
Table 2
Patient characteristics.
Median
(IQR)
2004 2006 2008
Age in years 10 (7;12) 12 (9;15) 14 (11;17)
FEV1%
predicted
93 (81;106) 96 (78;102) 91 (78;103)
Weight
z-score
−0.17 (−0.82;0.55) −0.32 (−0.83;0.43) −0.48 (−1.10;0.13)
IgG z-score −.01 (−1.08–1.25) .47 (−.57–1.85) .52 (−.44–2.05)
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CF children attending the CF center at the University of
Leuven, Belgium for follow-up were studied over a period of
4 years. Patients were included if above 5 years of age and able
to perform spirometry and if data were available for the years
2004 up to 2008. Maximum age at inclusion was 15 years.
Clinical data collected for each of the 3 monthly visits include:
spirometry with FEV1 and FVC% predicted, height and weight
(expressed as z-score) and sputum cultures. Total IgG was
measured twice yearly.
Sequential measurements for the years 2004, 2006 and 2008
were analyzed. For FEV1, the best pre-bronchodilator measure of
the year was used (expressed as percent predicted according to
Zapletal) [9]. Other parameterswere taken closest to the date of the
selected lung function. Weight z-score was calculated according
to Cole [10]. For each IgG result z-score was calculated using
mean and SD for age (Nephelometry, Beckman-Immage 800;
see Table 1).
Hypo-gammaglobulinemia was defined as IgG z-scoreb2
and hypergammaglobulinemia IgG as Ig z scoreN2.
Pa status was defined according to the Leeds criteria [11].
3. Statistics
Statistical analysis was performed with SPSS-18. For
continuous variables without normal distribution the Kruskal–
Wallis test was used. Non-parametric correlations (Spearman)
were calculated for cross-sectional and longitudinal data. For
multifactorial analysis linear regression was used.
4. Results
For 73 CF children between the age of 5 and 15 years in
2004, sequential data were available for the period 2004–2008
(40 boys, 33 girls). Chronic Pa infection was present in 12
patients (16%) in 2004, and 16 (22%) and 17 (23%) in 2006 and
2008 respectively. Further patient characteristics are given in
Table 2.
In 2004, 2 patients had an IgG z-scoreb2 (2.7%) and this
numberwas 1 (1.4%) and 2 (2.7%) in 2006 and 2008 respectively.
Twelve patients (16%) had an IgGN2 SD in 2004 and this number
increased to 14 (19%) and 18 (25%) in 2006 and 2008.
In cross-sectional analyses, there is an inverse correlation
between IgG z-scores and lung disease severity expressed as
FEV1% predicted (for 2004 r=−.455 and p=.001; for 2006 r=
−.264 and p= .02; for 2008 r=−.34 and p= .002). InTable 1
Reference values for serum IgG according to age as used by the lab.
Age −2 SD Mean +2 SD
3–6 years 4.78 8.04 11.29
6–9 years 5.30 9.18 13.06
9–12 years 5.58 9.06 12.54
12–16 years 5.76 9.21 12.65
N16 years 7.51 11.56 15.60longitudinal evaluation, changes in IgG z-score correlate
inversely with changes in FEV1 between 2004 and 2008 (r=
−.498 and pb .001). The average decline in FEV1% for a rise in
IgG of +1 z-score is −8.3% (95% CI −14.382–2.282). For the
subgroup of patients with chronic Pa infection in 2004
correlation between changes in IgG z-score and FEV1 was
−0.596 (p=0.01).
The mean change in IgG z-score over 4 years was 0.43 (SD
1.46) and the mean change FEV1% −5% (SD 17%). See Fig. 1.
We compared 3 groups of patients based on the IgG z-score
in 2004 (b−2, between −2 and +2 and above +2) the decline in
lung function from 2004 to 2008 or from 2004 to 2006 was not
significantly different for the 3 groups. We therefore cannot
suggest that a high IgG z-score early on can be used as a
predictor of future decline in lung function.
Correlation between IgG z-score and parameters of nutri-
tional status (BMI z-score, weight z-score and height z-score)
were weak and mostly non significant. For example for BMI z-
score and IgG z-score correlation did only reach significance for
the year 2008 r=−.268 p=.022*. Correlation between change
in IgG z-score and BMi z-score between 2008 and 2004 was .18
(p=.134).-40,00
-60,00
-4,00 -2,00
change in lgG z-score 2008-2004
00 2,00 4,00 6,00
Fig. 1. Correlation between change in IgG z-score 2008–2004 and change in
FEV1% 2008–2004.
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score, weak and non significant correlations were found: 2004
−0.152 p=.20; 2006 −.20 p=.084; 2008 −.226 p=.054 and for
change in IgG z-score and change in weight z-score between
2004 and 2008: −0.05 p=.65.
We performed a multifactorial analysis for the effect of age
and Pa status on IgG z-score. Pa status was not significantly
correlated with IgG z-score (p=0.8).
5. Discussion
We followed IgG levels in a cohort of 73 children with CF
over a 4 year period and correlated change in total serum IgG
with evolution of lung function. Most importantly increase in
IgG z-score inversely correlates with FEV1% decline over this
4 year period. In a cross sectional analysis, IgG expressed as z-
score also correlates with FEV1% predicted for the 3 separate
years of study (2004, 2006, and 2008).
Raised levels of IgG (N2 SD for age) were present in 12
(16%) patients at the start of the follow-up increasing to 18
(25%) 4 years later. The latter corresponds well with the 25.4%
of patients with an IgGN2 SD in the German CF registry [12]
for all patients under the age of 18 years. In some older
publications raised IgG was prevalent in up to 30% of patients
[13]. A pediatric report from 1980 [14] showed a prevalence of
hyper gammaglobulinemia in 22% of children below the age of
10 years. In the German registry, raised IgG levels occurred
more often in patients with chronic Pa infection. This was also
the case in our series, however, in multifactorial analysis age
rather than Pa status correlated with IgG z-score.
At the start and the end of the follow up (median age of 10
and 14 years), only 2 (2.7%) of the children had an IgGb2 SD
for age. This percentage is comparable to the report of Garside
et al. [8]. In the German CF registry (report of 2007), 3.5% of
pediatric patients had an IgGb2 SD however, the group
included children from birth. In studies published in the
seventies and eighties up to 11% of young CF children had
hypo-gammaglobulinemia [2]. This may be attributed to
malnutrition in older cohorts. To date there are however no
arguments that lower IgG level have a negative prognostic
value, even on the contrary [14].
The majority of reports on IgG levels in CF and correlation
with lung function are cross sectional. Only in a study published
in 1984 [5], longitudinal data over a period of 5 years were
documented while all other older studies report cross sectional
data on IgG and respiratory status. Compared with matched
controls, CF patients with hypo-gammaglobulinemia (b2 SD)
had a better prognosis [14].
We are aware of only 1 report correlating serum IgG with
respiratory status in children with CF published in the last
10 years [8]. In this series of 154 patients with a mean age of
9.2 years, 7.8% had IgGN2 SD. About 19% of children had
chronic Pa infection. The 12 patients with raised IgG had worse
lung function as well as clinical and X-ray scoring compared
with matched controls. In our report, a higher proportion of
patients had raised IgG levels (between 16% in 2004 and 25%
in 2008) although the age was comparable and the proportion ofchronic Pa somewhat lower. In the study of Garside et al. CF
children were included from diagnosis while in our study only
patients older than 5 years and above were studied.
Rather than matching patients according to raised or lowered
IgG levels, we correlated IgG and lung function evolution over
time in the whole cohort and found moderate correlation
(r=0.498) even better than the correlation between bronchoal-
veolar lavage elastase and FEV1 decline [15]. In addition, IgG
seemed responsive i.e. decreasing in subjects with improving
lung function and rising in subjects with worsening lung
function. The mean FEV% change per z-score change was
8.3%. To evaluate if higher IgG early on predict future decline
in lung function we compared 3 groups of patients based on the
IgG z-score in 2004. However, the change in lung function from
2004 to 2008 or from 2004 to 2006 was not significantly
different for the 3 groups. From our data it seems that change in
IgG z-score rather than z-score alone relates with lung function
evolution.
In a disease such as CF the specific nature of the IgG signal
(an overall reflection of lung function rather than a specific
antibody to one infection) may even be an advantage when used
as an outcome parameter. CF subjects indeed suffer from
different types of infection, viral as well as bacterial, and both
can contribute to lung disease.
We are aware that the cohort is not large, especially if one
would like to study subgroups with or without chronic Pa. On
the other hand, this cohort is followed up in the same CF
reference center and thus receives comparable treatment.
Our main message is that also in the current era of CF
treatment, IgG z-score in children with CF rises with age since
chronic lung infection is progressive. Since this rise is inversely
correlated with FEV1 it most likely reflects progressive chronic
lung infection. Raised IgG can thus be used in combination with
other measurements like lung function and imaging as an
additional parameter to evaluate if treatment is adequate or
should be intensified. Although hyper IgG is less frequently
found in young CF children, a rising IgG z-score in this group
should prompt a review of lung infectious status.
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